Wolfe Research downgraded Madrigal Pharmaceuticals (MDGL) to Peer Perform from Outperform.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- These Are the Most and Least Likely Biotech Takeover Targets for 2026
- Short Report: Vera Therapeutics bears retreat as stock rallies
- Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler
- Madrigal Pharmaceuticals price target raised to $581 from $456 at BofA
- Cautious Outlook for Madrigal Pharmaceuticals Amid Competitive Pressures and Adoption Challenges